• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245554 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& V9 s# ^' K5 W
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 " d% Y* Y, q+ i2 X" Y% e- w
+ Author Affiliations
0 c4 i8 Q0 V6 y1 |- z9 O7 |5 |2 I1 g3 e4 l0 {2 C
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan / |/ C2 D% Q: Y% k+ k! o
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* F' S# `6 {7 {2 {% O. l3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 n  A; t+ k6 i$ w3 F+ A) Q  p# p
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 0 U7 o1 k8 ?' k; c2 _1 I
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , G$ s. a1 i6 `
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : p+ q8 Z# [% |. T9 _) I* t1 E9 R
7Kinki University School of Medicine, Osaka 589-8511, Japan
: c& N, p/ h# j( d, s7 T2 Y8Izumi Municipal Hospital, Osaka 594-0071, Japan 1 S. }0 n- H9 K5 n# E- G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
  Z' w( a2 ]7 y' K2 m4 |0 z/ {, JCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 7 |, L0 C+ M8 d9 E' w
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. $ k$ ]9 o3 t- i% Z8 N/ g
: B% @* ~, y) V' g% y
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
' F/ k: F2 Y6 H6 n
! a% y& a+ x; |" DAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 2 M& w* P) l7 |8 X

& I( j; O9 x5 J2 [; c% l. ~5 jAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  % @, j9 C/ H2 ~3 h: G( D, i$ h# ~

4 P/ ~; ]8 h8 N' ?, yPublished online on: Thursday, December 1, 2011 7 z1 c, O% q. X9 C$ v3 k7 z2 v; b
( Y" q( f# b# Y$ F6 t! L+ j6 J
Doi: 10.3892/ol.2011.507
3 F2 a2 {) F1 H- V% d' k4 {9 a& Q2 l
; V) j+ ?& q" w# f, j, g* a3 gPages: 405-410 0 Z  \+ y# C, U0 c* X/ o  ~
$ U% x6 @& J4 |" l
Abstract:
- i2 S+ m6 V, u: I1 A* Z. B- WS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
; Y: ~4 F( J. t: V" h 0 R  O" v9 ~7 J0 z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
: J+ @4 G5 @3 t0 kF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
4 [$ ?: z* p; v/ A! f+ Author Affiliations
# S( X) F6 h, Y" b1 `# ]9 X& k1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu % [, l& @" X8 i6 _2 i
2Department of Thoracic Surgery, Kyoto University, Kyoto
3 v' b! O7 C. ^8 M3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 5 l4 E! e. f7 z( _, f
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
" @6 e( _9 X: B: Q8 DReceived September 3, 2010.
$ Y3 j) R+ B; N- ^2 r- N! YRevision received November 11, 2010.
8 l) k8 ~! `; |0 _5 MAccepted November 17, 2010.
" `' c% ?( N5 Q1 C- ]* [2 aAbstract
1 i( {. F8 o7 [5 i/ E5 qBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
$ X! I. l  M  ?+ DPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
3 G& _3 I. M( F9 N/ n! q) TResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
/ F% P5 N: Q$ @+ Y7 H1 R3 DConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
. |& Y. d1 ]$ ]2 e
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
$ d- z' v6 T! c* k今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?+ h& a4 |" q; X
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy9 K2 e6 q# p4 f% E0 p
http://clinicaltrials.gov/ct2/show/NCT01523587
  V: h, f5 `  X* {* Y9 B! x- B8 ^7 y
% ]5 F( X  ~6 s; y. n8 [BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC8 `; M4 j3 l* I* [
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
* ?% ^) @9 d4 x) V- A
+ F5 y6 ^; s& X' P2 a从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
( s  G7 G" y, Y- B, L! z至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
' s: K- M+ ^" T7 m$ Y
没有副作用是第一追求,效果显著是第二追求。
* s! f3 E4 D: G' p9 J不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表